DexCom, Inc. (NASDAQ:DXCM) Stake Reduced by XTX Topco Ltd

XTX Topco Ltd cut its stake in DexCom, Inc. (NASDAQ:DXCM) by 65.6% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 10,016 shares of the medical device company’s stock after selling 19,088 shares during the period. XTX Topco Ltd’s holdings in DexCom were worth $779,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in DXCM. Mariner LLC increased its holdings in shares of DexCom by 1.5% in the 4th quarter. Mariner LLC now owns 29,729 shares of the medical device company’s stock worth $2,312,000 after acquiring an additional 442 shares during the period. Sagespring Wealth Partners LLC acquired a new stake in shares of DexCom in the fourth quarter valued at approximately $418,000. Townsquare Capital LLC increased its stake in shares of DexCom by 288.7% in the fourth quarter. Townsquare Capital LLC now owns 37,191 shares of the medical device company’s stock valued at $2,892,000 after purchasing an additional 27,623 shares during the period. Crux Wealth Advisors acquired a new position in shares of DexCom during the fourth quarter worth approximately $245,000. Finally, Qtron Investments LLC acquired a new position in shares of DexCom during the fourth quarter worth approximately $766,000. 97.75% of the stock is currently owned by institutional investors.

DexCom Trading Down 0.2 %

NASDAQ:DXCM opened at $68.59 on Friday. The stock has a fifty day simple moving average of $75.33 and a 200 day simple moving average of $76.59. The company has a quick ratio of 1.28, a current ratio of 1.47 and a debt-to-equity ratio of 0.59. The firm has a market capitalization of $26.90 billion, a price-to-earnings ratio of 47.97, a price-to-earnings-growth ratio of 2.30 and a beta of 1.50. DexCom, Inc. has a 1-year low of $57.52 and a 1-year high of $139.24.

DexCom (NASDAQ:DXCM) last released its earnings results on Thursday, February 13th. The medical device company reported $0.45 earnings per share for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. Sell-side analysts forecast that DexCom, Inc. will post 2.03 earnings per share for the current year.

Insider Activity

In related news, EVP Michael Jon Brown sold 13,000 shares of the firm’s stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $70.38, for a total transaction of $914,940.00. Following the completion of the sale, the executive vice president now directly owns 105,602 shares in the company, valued at approximately $7,432,268.76. This trade represents a 10.96 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Kevin R. Sayer sold 32,498 shares of the company’s stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $70.38, for a total transaction of $2,287,209.24. Following the completion of the transaction, the chief executive officer now owns 372,029 shares in the company, valued at approximately $26,183,401.02. This represents a 8.03 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 105,009 shares of company stock worth $8,044,178 over the last quarter. Corporate insiders own 0.32% of the company’s stock.

Analysts Set New Price Targets

Several analysts have weighed in on DXCM shares. Baird R W raised DexCom from a “hold” rating to a “strong-buy” rating in a research note on Thursday, January 16th. Wells Fargo & Company reaffirmed an “overweight” rating on shares of DexCom in a report on Saturday, March 8th. Redburn Atlantic raised shares of DexCom from a “neutral” rating to a “buy” rating and raised their target price for the company from $85.00 to $115.00 in a research note on Monday, February 3rd. Cfra Research raised shares of DexCom to a “hold” rating in a research note on Friday, March 21st. Finally, Morgan Stanley raised their price objective on shares of DexCom from $75.00 to $82.00 and gave the company an “equal weight” rating in a research note on Friday, February 14th. Five research analysts have rated the stock with a hold rating, thirteen have given a buy rating and three have assigned a strong buy rating to the company’s stock. According to MarketBeat.com, DexCom presently has a consensus rating of “Moderate Buy” and an average target price of $99.00.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.